KR20090082476A - 분말의 혼합 방법 - Google Patents

분말의 혼합 방법 Download PDF

Info

Publication number
KR20090082476A
KR20090082476A KR1020097012026A KR20097012026A KR20090082476A KR 20090082476 A KR20090082476 A KR 20090082476A KR 1020097012026 A KR1020097012026 A KR 1020097012026A KR 20097012026 A KR20097012026 A KR 20097012026A KR 20090082476 A KR20090082476 A KR 20090082476A
Authority
KR
South Korea
Prior art keywords
spray
powder
particles
nanoparticles
drying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097012026A
Other languages
English (en)
Korean (ko)
Inventor
토르슈텐 슐츠-파뎀레흐트
잔드라 지몬트코브스키
패트릭 가리델
한스-요아힘 케른
클라우스-위르겐 슈테펜스
Original Assignee
베링거 잉겔하임 파르마 게엠베하 운트 코 카게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 filed Critical 베링거 잉겔하임 파르마 게엠베하 운트 코 카게
Publication of KR20090082476A publication Critical patent/KR20090082476A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/04—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a gaseous medium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020097012026A 2006-11-10 2007-11-08 분말의 혼합 방법 Ceased KR20090082476A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006053375.5 2006-11-10
DE102006053375A DE102006053375A1 (de) 2006-11-10 2006-11-10 Verfahren zur Mischung von Pulvern

Publications (1)

Publication Number Publication Date
KR20090082476A true KR20090082476A (ko) 2009-07-30

Family

ID=39099637

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097012026A Ceased KR20090082476A (ko) 2006-11-10 2007-11-08 분말의 혼합 방법

Country Status (8)

Country Link
US (1) US20100143331A1 (enExample)
EP (1) EP2091518B1 (enExample)
JP (1) JP2010509287A (enExample)
KR (1) KR20090082476A (enExample)
CA (1) CA2669009A1 (enExample)
DE (1) DE102006053375A1 (enExample)
TW (1) TW200829285A (enExample)
WO (1) WO2008055951A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US9072664B2 (en) 2008-05-22 2015-07-07 3M Innovative Properties Company Process for manufacturing flowable powder drug compositions
CN102292072A (zh) 2009-01-26 2011-12-21 特瓦制药工业有限公司 用微粒包衣载体的方法
WO2010118480A1 (en) * 2009-04-17 2010-10-21 Commonwealth Scientific And Industrial Research Organisation A process and apparatus for depositing nanostructured material onto a substrate material
ES2814336T3 (es) * 2012-04-13 2021-03-26 Glaxosmithkline Ip Dev Ltd Partículas de agregado
CA2899936A1 (en) * 2013-02-15 2014-08-21 Wellmark International Mineral feed-through formulation
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
WO2025075208A1 (ja) * 2023-10-05 2025-04-10 ナガセヴィータ株式会社 吸入用粉末剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB866038A (en) * 1957-10-18 1961-04-26 Air Reduction Polyvinyl acetate powder and method of making the same
US3842888A (en) * 1969-12-15 1974-10-22 Colgate Palmolive Co Apparatus for introducing ingredients into a spray drying tower
GB8622565D0 (en) * 1986-09-19 1986-10-22 Unilever Plc Detergent composition
JPH0776527A (ja) * 1993-06-28 1995-03-20 Hayashibara Biochem Lab Inc 半固形製剤とその製造方法
JPH08302399A (ja) * 1995-05-09 1996-11-19 Lion Corp 熱風噴霧乾燥方法
JPH1094726A (ja) * 1996-09-24 1998-04-14 Tokin Corp 乾式成形用粉末の製造方法
ATE284677T1 (de) * 1997-03-20 2005-01-15 Schering Corp Herstellung von pulveragglomeraten
WO1999055362A1 (en) * 1998-04-29 1999-11-04 Genentech, Inc. Spray dried formulations of igf-i
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
JP3363438B2 (ja) * 2000-05-02 2003-01-08 ビオフェルミン製薬株式会社 噴霧乾燥による菌体乾燥物
JP4125512B2 (ja) * 2000-11-29 2008-07-30 伊藤ハム株式会社 粉末製剤及びその製造方法
CA2430318C (en) * 2000-11-29 2009-10-27 Itoham Foods Inc. Powder formulation and method for producing the same
WO2002055101A2 (en) * 2000-12-21 2002-07-18 Inhale Therapeutic Syst Storage stable powder compositions of interleukin-4 receptor
WO2003024396A2 (en) * 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
US7202791B2 (en) 2001-09-27 2007-04-10 Koninklijke Philips N.V. Method and apparatus for modeling behavior using a probability distrubution function
TW200300696A (en) * 2001-11-01 2003-06-16 Inhale Therapeutic Syst Spray drying methods and related compositions
JP4015593B2 (ja) * 2002-09-04 2007-11-28 株式会社パウレック 流動層装置
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
MXPA05007158A (es) * 2002-12-31 2005-09-21 Nektar Therapeutics Formulacion farmaceutica con un agente activo insoluble.
CA2435632A1 (en) * 2003-07-21 2005-01-21 Warren Hugh Finlay Formulation of powder containing nanoparticles for aerosol delivery to the lung
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
US20050191246A1 (en) * 2003-12-13 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powders comprising low molecular dextran and methods of producing those powders
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) * 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
DE102004022928A1 (de) * 2004-05-10 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulver enthaltend neuartige Oligosacharidgemische und Verfahren zu deren Herstellung
US7727962B2 (en) * 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
DE102006030164A1 (de) * 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Pulver

Also Published As

Publication number Publication date
EP2091518B1 (de) 2013-09-11
WO2008055951A1 (de) 2008-05-15
US20100143331A1 (en) 2010-06-10
DE102006053375A1 (de) 2008-05-15
JP2010509287A (ja) 2010-03-25
EP2091518A1 (de) 2009-08-26
CA2669009A1 (en) 2008-05-15
TW200829285A (en) 2008-07-16

Similar Documents

Publication Publication Date Title
JP7305842B2 (ja) 結晶性の医薬のジケトピペラジン組成物を含む乾燥粉末
JP5859433B2 (ja) 規定された比表面積を有するジケトピペラジン微粒子
KR102465025B1 (ko) 열-안정성 건조 분말 약제학적 조성물 및 방법
CA2654264C (en) Inhalant powder containing phenylalanine
KR20090082476A (ko) 분말의 혼합 방법
Salústio et al. Different carriers for use in dry powder inhalers: characteristics of their particles
US20080071064A1 (en) Tempering
JP2025185031A (ja) 薬物送達システム
HK1261654B (zh) 微晶二酮哌嗪组合物以及方法
WO2002024175A2 (en) Pharmaceutical formulation for pulmonary or nasal administration
HK1219097B (en) Microcrystalline diketopiperazine compositions and methods

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090610

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20121107

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140227

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140730

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140227

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I